Alfred Scheidegger
About Alfred Scheidegger
Alfred Scheidegger is an experienced corporate leader with over 35 years in management and development within the biopharma industry. He currently serves as Chairman of the Board of Directors at Wemedoo AG and Vice Chairman at Dottikon Exclusive Synthesis AG, while also holding advisory roles at BioNeex UG.
Current Role at Wemedoo AG
Alfred Scheidegger serves as the Chairman of the Board of Directors at Wemedoo AG since 2023. In this role, he provides strategic oversight and guidance to the organization, leveraging his extensive experience in corporate development and management. His leadership is focused on advancing the company's objectives and fostering growth within the biopharma sector.
Professional Experience and Advisory Roles
Scheidegger has a diverse professional background, including his current position as a Member of the Advisory Board at BioNeex UG since 2024. He previously held various board positions, including at TRACON Pharmaceuticals and Palyon Medical Corporation. His experience spans over 35 years, with significant roles in corporate governance and advisory capacities across multiple organizations.
Educational Background and Expertise
Alfred Scheidegger holds a Doctor of Philosophy (PhD) in microbiology and biochemistry from the University of Basel, Switzerland. He completed postdoctoral research training in enzymology at Kyoto University, Japan. Additionally, he studied Business Administration and Management at Harvard Business School, completing an executive training program. His educational background supports his profound expertise in medical innovation and the biopharma industry.
Achievements in Biopharma Industry
Scheidegger has played a pivotal role in establishing BioNeex as a leading platform for collaborations within the biopharma industry. His strong focus on fostering licensing and co-development alliances is evident in his strategic initiatives at BioNeex. His extensive experience in R&D business development further enhances his contributions to the field.
International Experience and Network
With over 35 years of experience, Scheidegger possesses a robust understanding of Asian business markets, which has contributed to his extensive international network. His work in various countries, including Singapore and Japan, has equipped him with valuable insights into global business dynamics, particularly within the biopharma sector.